Post-treatment care program for breast and prostate cancer survivors
Cancer Survivors Program: Effectiveness of Monitoring Adverse Events After Completion of Curative Treatment for Breast and Prostate Cancer
This program tests whether a focused questionnaire plus quality-of-life screening can detect and help manage side effects in people who have finished curative treatment for breast or prostate cancer.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Masaryk Memorial Cancer Institute Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Brno) |
| Trial ID | NCT07253987 on ClinicalTrials.gov |
What this trial studies
This pilot implements an active screening program using a comprehensive questionnaire and quality-of-life measures to identify physical, psychological, social, occupational, and financial effects after completion of curative cancer therapy. The tool is designed to align with ESMO survivorship recommendations and to highlight opportunities for lifestyle interventions and early detection of recurrence. Eligible participants are adults with histologically confirmed invasive breast or prostate cancer who have completed the acute phase of curative treatment and are available for follow-up within 12 months. The program is being tested at the Masaryk Memorial Cancer Institute to inform follow-up planning and timely referrals.
Who should consider this trial
Good fit: Adults (age 18+) with histologically confirmed invasive breast or prostate cancer who have completed curative-intent treatments and are within 12 months of finishing the acute phase of therapy are ideal candidates.
Not a fit: Patients currently receiving active oncological therapy (other than permitted adjuvant hormonal, targeted, or immunotherapy), those with recurrent disease, patients whose breast cancer did not include chemotherapy, or individuals more than 12 months from treatment completion are unlikely to benefit from this pilot.
Why it matters
Potential benefit: If successful, the program could help clinicians detect ongoing or late treatment-related problems earlier and guide tailored follow-up and lifestyle interventions to improve survivors' quality of life.
How similar studies have performed: Similar survivorship screening programs and questionnaires have been used in other centers and have shown benefit in identifying unmet needs and improving referrals, though standardized approaches are still evolving.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * The patient understands the information provided and agrees to participate in the study. * Age 18 years or older. * Histologically confirmed invasive breast cancer or invasive prostate cancer. * Completion of the acute phase of curative oncological therapy: * for breast cancer: curative surgery performed + completed neoadjuvant/adjuvant chemotherapy and completed adjuvant radiotherapy, if indicated * for prostate cancer: completed radiotherapy with curative intent or radical prostatectomy performed (open, laparoscopic, robotic) or completed adjuvant radiotherapy after prostatectomy * The patient is available for follow-up within 12 months of enrollment in the study. Exclusion Criteria: * Active ongoing oncological therapy (except for (i) adjuvant hormone therapy, (ii) adjuvant targeted therapy (anti-HER2 therapy, CDK4/6i, PARPi, T-DM1), (iii) adjuvant immunotherapy) * Neoadjuvant/adjuvant therapy did not include chemotherapy (breast cancer). * Recurrence of cancer * Metastatic disease * History of other primary malignancy (except for non-melanoma skin cancer)
Where this trial is running
Brno
- Masaryk Memorial Cancer Institute — Brno, Czechia (Recruiting)
Study contacts
- Study coordinator: Lenka Pavčíková, MUDr.
- Email: lenka.pavcikova@mou.cz
- Phone: +420 543 136 136
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.